ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
The FDA has accepted aldeyra therapeutics' (ALDX.US) application for market approval of a potential "first-in-class" therapy for dry eye disease.
Aldeyra Therapeutics (ALDX.US) announced that the USA FDA has accepted its resubmitted New Drug Application (NDA) for reproxalap, an innovative ophthalmic drug for the treatment of dry eye disease.
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $11
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA
Market-Moving News for November 18th
Express News | Aldeyra Therapeutics: Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co if Option Is Exercised
